Arch Scientists Successfully Image Brain Tumour Initiating Cells Using MRI

Arch Biopartners Inc ("Arch") (CNSX:ACH)(OTCBB:FOIFF) today announced Arch
scientists have successfully used magnetic resonance imaging ("MRI") to detect
human brain tumour initiating cells in mice using Arch's proprietary cell
targeting technology. 


Brain tumour initiating cells (known as "BTICs") are believed to be the disease
reservoirs of malignant glioma, which escape clinical intervention. Until now
these cells were not visible using current diagnostic imaging techniques.


Malignant glioma is one of the deadliest brain cancers. The average patient with
malignant glioma has a life expectancy of approximately 1 year and "long-term
survivors" (i.e. surviving greater than or equal to 3 years) are rare. The main
cause of death is recurrence of tumours post-therapy, which is believed to
result from undetected and untreated disease reservoirs.


Arch anticipates that the imaging of BTICs will lead to improvements in the
surgical and therapeutic management of brain tumours. 


A longer term objective is to adapt Arch's proprietary targeting molecules to
deliver anti-cancer drugs directly to BTICs and other brain cancer cells.


About Arch Biopartners

Arch Biopartners is a portfolio based biotechnology company established to
develop new products and technology for sale to pharmaceutical and industrial
companies. 


Arch is developing non-invasive diagnostic and therapeutic molecules for brain
cancer through its fully owned subsidiary, Arch Cancer Therapeutics ("ACT").
These molecules are specialized peptides proprietary to ACT that target and
identify BTICs and invasive brain cancer cells that are not normally seen using
current diagnostic imaging techniques. 


For more information on Arch, please consult the other public documents filed on
SEDAR at www.sedar.com. 


The company's website address is: www.archbiopartners.com.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release
are forward looking statements that involve various risks and uncertainties,
including, without limitation, statements regarding the future plans and
objectives of Arch. There can be no assurance that such statements will prove to
be accurate. Actual results and future events could differ materially from those
anticipated in such statements. These and all subsequent written and oral
forward-looking statements are based on the estimates and opinions of management
on the dates they are made and are expressly qualified in their entirety by this
notice. Arch assumes no obligation to update forward-looking statements should
circumstances or management's estimates or opinions change.